BerandaSBHMY • OTCMKTS
add
Sino Biopharmaceutical Unsponsored Caymand Islands ADR
Tutup sebelumnya
$9,05
Rentang tahun
$6,69 - $9,65
Kapitalisasi pasar
61,62Â M HKD
Volume Rata-Rata
50,00
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(CNY) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 7,94Â M | 11,14% |
Biaya operasional | 4,78Â M | 10,58% |
Laba bersih | 1,51Â M | 139,69% |
Margin laba bersih | 19,01 | 115,78% |
Penghasilan per saham | — | — |
EBITDA | 1,98Â M | 8,88% |
Tarif pajak efektif | 16,99% | — |
Neraca
Total aset
Total liabilitas
(CNY) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 13,18Â M | -15,93% |
Total aset | 66,70Â M | 1,62% |
Total liabilitas | 24,58Â M | -15,76% |
Total ekuitas | 42,12 M | — |
Saham yang beredar | 18,21 M | — |
Harga terhadap nilai buku | 5,03 | — |
Tingkat pengembalian aset | 6,50% | — |
Tingkat pengembalian modal | 8,37% | — |
Arus Kas
Perubahan kas bersih
(CNY) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | 1,51Â M | 139,69% |
Kas dari operasi | 1,54Â M | 15,25% |
Kas dari investasi | -1,02Â M | 49,91% |
Kas dari pembiayaan | -2,05Â M | -1,42% |
Perubahan kas bersih | -1,52Â M | 43,37% |
Arus kas bebas | 1,09Â M | 36,59% |
Tentang
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a civilian-run enterprise principally engaged in the medicine products business in Mainland China.
Being a member of Charoen Pokphand Group and headquartered in Hong Kong and Beijing, Sino Biopharm is engaged in researching, developing, producing, and selling biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis through its subsidiaries.
Sino Biopharm is also involved in other minor businesses through its subsidiaries, such as properties, health food, optical glass, optical and auditory products. Wikipedia
CEO
Didirikan
2000
Situs
Karyawan
24.437